ANXA1 and non-small cell lung carcinoma: Removal of any of the known DAMPs that are required for ICD including ANXA1, ATP, CALR, or HMGB1 abolished the capacity of crizotinib plus CDDP-treated NSCLC cells to elicit an anticancer immune response in vaccination assays.